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Approximately half of poor prognosis neuroblastomas (NBs) are characterized by patho-
gnomonic MYCN gene amplification and MYCN over-expression. Here we present data
showing that short-interfering RNA mediated depletion of the protein arginine methyl-
transferase 5 (PRMT5) in cell-lines representative of NBs with MYCN gene amplification
leads to greatly impaired growth and apoptosis. Growth suppression is not apparent in
the MYCN-negative SH-SY5Y NB cell-line, or in two immortalized human fibroblast
cell-lines. Immunoblotting of NB cell-lines shows that high PRMT5 expression is strongly
associated with MYCN-amplification (P < 0.004, ManneWhitney U-test) and immunohis-
tochemical analysis of primary NBs reveals that whilst PRMT5 protein is ubiquitously ex-
pressed in the cytoplasm of most cells, MYCN-amplified tumours exhibit pronounced
nuclear PRMT5 staining. PRMT5 knockdown in MYCN-overexpressing cells, including
the SHEP-21N cell-line with inducible MYCN expression leads to a dramatic decrease in
MYCN protein and MYCN-associated cell-death in SHEP-21N cells. Quantitative gene
expression analysis and cycloheximide chase experiments suggest that PRMT5 regulates
MYCN at a post-transcriptional level. Reciprocal co-immunoprecipitation experiments
demonstrated that endogenous PRMT5 and MYCN interact in both SK-N-BE(2)C and
NGP cell lines. By using liquid chromatography e tandem mass spectrometry (LC-MS/
MS) analysis of immunoprecipitated MYCN protein, we identified several potential sites
of arginine dimethylation on the MYCN protein. Together our studies implicate PRMT5
in a novel mode of MYCN post-translational regulation and suggest PRMT5 plays a majoraboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD,
091.
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novel therapeutic strategy for neuroblastoma and other cancers driven by the MYCN
oncogene.
ª 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction arginine methyltransferase 5 (PRMT5). PRMT5 is active inNeuroblastoma (NB) is an embryonal malignancy arising
from the sympathetic nervous system and is one of the com-
monest solid tumours of childhood. The development of NB
is believed to be contingent on defective differentiation of
neural crest cells, although the precise cell of origin remains
unknown. Several genetic markers are found in poor prog-
nosis NB, including loss of chromosome 1p, loss of 11q,
gain of 17q and, most notably, amplification of the MYCN
proto-oncogene which occurs in about 50% of high-risk
NBs (w20% of total NBs) (Brodeur, 2003; Maris et al., 2007).
Importantly, in some tumours, MYCN protein levels can
also be very high without gene amplification or high mRNA
levels, implicating other factors that might stabilize MYCN
at the protein level; as expected, high MYCN protein is
closely associated with very poor prognosis (Valentijn
et al., 2012). MYCN is a classical oncogenic transcription fac-
tor and its aberrant expression is thought to deregulate neu-
roblast differentiation programmes by a variety of means,
including recruitment of gene repressing components of
the epigenetic machinery, such as histone deacetylases
(Iraci et al., 2011) and Polycomb proteins such as EZH2
(Corvetta et al., 2013), the latter being a histone methyltrans-
ferase (HMT) independently shown to repress tumour sup-
pressor genes in neuroblastoma (Wang et al., 2012). Genes
repressed by MYCN include neurotrophic tyrosine kinase re-
ceptor (NTKR) and nerve growth factor receptor (NGFR) (Iraci
et al., 2011), and alleviating these blocks is conducive to trig-
gering apoptosis.
The possibilities of neuroblastoma therapeutics based on
targeting of MYCN have advanced recently, notably with the
demonstration that small molecule inhibitors targeting
Aurora kinase A such as Alisertib (MLN8237) can trigger deple-
tion of MYCN protein in NB cell-lines and in themurinemodel
of NB, leading to NB growth inhibition and tumour regression.
MYCN destabilisation is not contingent on Aurora kinase A
enzymatic activity, but rather on its conformation and ability
to protect MYCN from FBXW7-mediated degradation (Otto
et al., 2009; Brockmann et al., 2013). Another promising class
of inhibitor targeting the MYC family is exemplified by JQ-1,
which acts by inhibiting bromodomain and extra terminal
domain (BET) family of proteins and thereby curtailing
MYCN transcription (Puissant et al., 2013).
Given the increasing evidence for the importance of gene
repression by histone modifications in neuroblastoma
tumorigenesis cited above, we assessed another histone
methyltransferase (HMT) known to catalyse repressive epige-
neticmodifications in a variety of cancers, specifically proteinchromatin remodelling complexes, and catalyses symmetric
dimethylation of the histone 3 tail at arginine 8 (H3R8) and
histone 4 arginine 3 (H4R3), and is one of two “type II” argi-
nine methyltransferases, the other being PRMT7 (Karkhanis
et al., 2011; Yang and Bedford, 2013). PRMT5 over-
expression in a variety of cancers is thought to silence
tumour suppressor genes (TSGs) such as ST7 (suppression
of tumorigenicity 7) (Pal et al., 2004) and genes encoding RB
family proteins (Chung et al., 2013; Yang and Bedford, 2013).
PRMT5 also facilitates gene silencing with DNA methyltrans-
ferase 3A (Zhao et al., 2009) and the Polycomb repressor com-
plex (Chung et al., 2013). As well as TSG silencing, PRMT5-
mediated methylation of non-histone proteins is a further
alternative oncogenic modality for PRMT5. This is exempli-
fied by Programmed cell death 4 (PDCD4) protein in breast
cancer, which shows increased tumorigenicity when over-
expressed with PRMT5 in an orthotopic model of breast can-
cer (Powers et al., 2011). Other proteins post-translationally
methylated by PRMT5 include the transcription factors p53
(Jansson et al., 2008), NF-kB (Wei et al., 2013) and E2F-1 (Cho
et al., 2012; Zheng et al., 2013).
In this report we provide evidence showing that PRMT5 is
involved in poor prognosis NB, and is a key post-translational
regulator of the MYCN oncoprotein. PRMT5 inhibition may
therefore represent a novel alternative for treatment of NB
and other cancers driven by the MYCN oncoprotein.2. Materials & methods
2.1. Cell Culture, transfections and protein/RNA
preparation
Neuroblastoma cell lines used in this study were purchased
from Deutsche Sammlung von Mikroorganismen und Zell-
kulturen (DSMZ) or kindly provided by The Children’s
Oncology group (http://www.cogcell.org), Manfred Schwab
(German Cancer Research Center), Robert Ross, (Fordham
University), Carmel McConville, (University of Birmingham),
Pramila Ramani (University of Bristol). Cells were cultured in
Dulbecco’s modified eagle’s medium (DMEM):F12-HAM
(Sigma) supplemented with 10% foetal bovine serum (PAA
Cell Culture), 200 mM L-Glutamine, 100 mM penicillin,
0.1 mg/mL streptomycin (Sigma) and 1% (v/v) non-essential
amino acids (Life technologies). SHEP-Tet21N cells were
cultured in RPMI 1640 supplemented with 10%
tetracycline-free foetal bovine serum (Life technologies)
with tetracycline added to 1 mg/ml. Human fibroblast lines
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Institute Cell Repository stably transfected with human telo-
merase reverse transcriptase (kindly supplied by Grant
Stewart, University of Birmingham), and were grown in
DMEM with 10% foetal bovine serum. All cells were myco-
plasma free, and cultured as adherent monolayers at 37 C
with 5% CO2.
For short-interfering RNA (siRNA) treatments, exponen-
tially growing cells were reverse-transfected using Lipofect-
amine 2000 (Life technologies) at a final concentration of
25e50 nM according to the manufacturer’s instructions. After
48e72 h, cells were lysed for protein in Cell signalling lysis
buffer (New England Biolabs), or for RNA in QIAzol (QIAGEN).
Total RNA was DNAsed and purified using the miRNeasy
Mini Kit (QIAGEN). Details of siRNAs (Sigma) are given in
Supplemental Table 1.
Cell counts were done in quadruplicate and repeated at
least twice using a Countess cell-counter (Invitrogen). Photo-
graphs were taken with a Leica microscope camera using
Spot Advanced software.
2.2. Cycloheximide (CHX) chase experiments and
inhibitor studies
To assess protein stability, cells were treated with 50 mg/ml
cycloheximide (Sigma) following siRNA transfection for 72 h.
At the given timepoints, cells were washed in ice-cold PBS
and prepared for SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) as below. For inhibition of apoptosis, siRNA trans-
fected cells were treated with 10 mM caspase inhibitor Q-VD-
OPh (QVD, Sigma) 24 h after knockdown.
2.3. Co-immunoprecipitations
Cells were lysed in Cell Signalling Lysis buffer complemented
with Complete Mini Protein inhibitors (Roche), 5 mM dithio-
threitol and 10% (v/v) glycerol, and sonicated using a Bio-
ruptor (Diagenode). The co-immunoprecipitations were
carried out according to the manufacturer’s protocol
(Dynabeads Protein G Immunoprecipitation Kit, Life Sci-
ences Technology). Briefly, for each immunoprecipitation
8 mg antibody was conjugated to 50 mL Protein-G magnetic
beads (Millipore). After preclearing with normal mouse or
rabbit IgG, 500 mg protein lysate was incubated overnight
with the antibody-coated beads at 4 C with rotation. Beads
were washed twice in IP lysis buffer and once in PBS and
boiled in 1 Laemmli sample buffer (312.5 mM TriseHCl pH
7.4, 50% (v/v) glycerol, 10% (w/v) SDS (Sodium Dodecyl Sul-
phate; Fisher Scientific), 5% (v/v) 2-Mercaptoethanol (Sigma)
before SDS-PAGE.
2.4. Immunoblotting and immunohistochemistry
Immunoblotting and immunohistochemistry were per-
formed as described previously (Szemes et al., 2013). Neuro-
blastoma sections were from archival tissues collected at
The Children’s Hospital at Westmead Histopathology Depart-
ment since 1950, and assembled into a tissue microarray con-
taining 49 cases. Full details of the TMA are published
(Chetcuti et al., 2014). For immunohistochemistry primaryanti-PRMT5 antibody was used at a dilution of 1:300. Details
of other antibodies and dilutions used are given in
Supplemental Table 1.
2.5. Gene expression analysis
Quantitative real-time reverse transcriptase-PCR (qRT-PCR)
was performed as previously described (Szemes et al., 2013).
Details of primers used (Sigma) are given in Supplemental
Table 1.
2.6. Flow cytometry analysis
For analysis of DNA content, cells were harvested, rinsed in
phosphate-buffered saline (PBS), permeabilised in ice cold
70% ethanol, and stored at 4 C overnight. Before
fluorescence-activated cell-sorting (FACs), cells were washed
with PBS, treated with 100 mg/ml RNase A (Qiagen) and then
stained with 50 mg/ml propidium iodide (Sigma) for 30 min in
the dark at 37 C. DNA content of propidium iodide stained
cells was measured on a LSRFortessa X-20 (BD Biosciences)
and data analysed using ModFit LT (Verity Software House).
All assays were conducted on triplicate samples unless other-
wise stated.
2.7. Liquid chromatography e tandem mass
spectrometry (LC-MS/MS) analysis
MYCN was immunoprecipitated as described above from
control and PRMT5 siRNA-treated SK-N-BE(2)C cells. Prior
to harvest, cells were treated with 20 mg/ml MG132 for 2 h
to circumvent possible proteosomal degradation of unme-
thylated MYCN. Protein was fractionated by SDS-PAGE using
SYPRO Ruby (Invitrogen) staining and visualised using a
Typhoon 9400 variable mode imager (GE Healthcare). Pro-
teins equal or above the MYCN band were excised and sub-
jected to in-gel tryptic digestion using a Pro-Gest automated
digestion unit (Digilab UK). The resulting peptides were frac-
tionated using a Dionex UltiMate 3000 nano HPLC system in
line with an LTQ-Orbitrap Velos mass spectrometer (Thermo
Scientific). In brief, peptides in 1% (v/v) formic acid were
injected onto an Acclaim PepMap C18 nano-trap column
(Dionex). After washing with 0.5% (v/v) acetonitrile 0.1% (v/
v) formic acid peptides were resolved on a
250 mm  75 mm Acclaim PepMap C18 reverse phase analyt-
ical column (Dionex) over a 150 min organic gradient, using 7
gradient segments (1e6% solvent B over 1 min, 6e15% B over
58 min, 15e32%B over 58 min, 32e40%B over 3 min, 40e90%B
over 1 min, held at 90%B for 6 min and then reduced to 1%B
over 1 min) with a flow rate of 300 nl min1. Solvent A was
0.1% formic acid and Solvent B was aqueous 80% acetonitrile
in 0.1% formic acid. Peptides were ionized by nano-
electrospray ionization at 2.1 kV using a stainless steel
emitter with an internal diameter of 30 mm (Thermo Scienti-
fic) and a capillary temperature of 250 C. Tandem mass
spectra were acquired using an LTQ-Orbitrap Velos mass
spectrometer controlled by Xcalibur 2.1 software (Thermo
Scientific) and operated in data-dependent acquisition
mode. The Orbitrap was set to analyse the survey scans at
60,000 resolution (at m/z 400) in the mass range m/z
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duty cycle selected for MS/MS in the LTQ linear ion trap.
Charge state filtering, where unassigned precursor ions
were not selected for fragmentation, and dynamic exclusion
(repeat count, 1; repeat duration, 30 s; exclusion list size,
500) were used. Fragmentation conditions in the LTQ were
as follows: normalized collision energy, 40%; activation q,
0.25; activation time 10 ms; and minimum ion selection in-
tensity, 500 counts.
The raw data files were processed and converted into mgf
text files using Proteome Discoverer software v1.2 (Thermo
Scientific). The mgf files were submitted to the Mascot search
algorithm (Matrix Science, London UK) and searched against
the UniProt human database (May 2014 9606_2014_05, 156503
sequences; 55255217 residues), using the following settings:
peptide precursor mass tolerance was set at 10 ppm, and
MS/MS tolerance was set at 0.8 Da. Search criteria included
carbamidomethylation of cysteine (þ57.0214) as a fixed modi-
fication and oxidation of methionine (þ15.9949) and methyl-
ation of arginine (þ14.0157, þ28.0314) and lysines (þ14.0157,
þ28.0314, þ42.0471) as variable modifications. Searches were
performed using trypsin as the enzyme with one missed
cleavage. The reverse database search option was enabledFigure 1 e PRMT5 knockdowns induce apoptosis in SK-N-BE(2)C cells.
EZH2 and PRMT5 induced varying degrees of SK-N-BE(2)C growth inhib
is also shown (siVE). Cell death was rescuable using QVD. (B) Percentage
with (white bars) QVD treatment. Significant differences are shown by ast
apoptosis by immunoblotting for cleaved PARP (cPARP) (lower panel).and all peptide data was filtered to satisfy false discovery
rate (FDR) of 5%. Any modified peptides which were identified
by Mascot were manually verified by examining the raw MS/
MS data.
2.8. Quantitative and statistical analyses
Gel images were quantified using Image J software, and Stu-
dent’s t-test andManneWhitney testswere used for statistical
analysis.3. Results and discussion
3.1. PRMT5 knockdown leads to apoptosis of
neuroblastoma cells
We evaluated the effect of short-interfering RNA (siRNA) e
mediated PRMT5 depletion on the SK-N-BE(2)C cell-line, repre-
sentative of the poor prognosis subset of NB, togetherwith two
other HMTs known to be involved in cancer. Knockdown of
CARM1 (PRMT4), EZH2 and PRMT5 all induced some cell death
in SK-N-BE(2)C cells, but PRMT5 depletion triggered a(A) Short-interfering RNAs (siRNAs) targeting CARM1/PRMT4,
ition and cell death after 72 h incubation. The negative control siRNA
of dead cells per siRNA treatment are shown without (black bars) and
erisks (P< 0.05). (C) Verification of knockdowns (upper panel) and
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death compared to the negative control siRNA, and substan-
tially greater death than either CARM1 or EZH2 knockdowns.
Treatment of knockdowns with the caspase inhibitor Q-VD-
OPh rescued cell death, and apoptosis was further confirmed
by immunoblotting for poly(ADP-ribose) polymerase-1 (PARP-
1) cleavage (Figure 1AeC). PRMT5 depletion also induced cell
death inNGP cells, but not in SH-SY5YNB cells or normal fibro-
blasts, despite efficient knockdowns (Figure 2 and Figure S1).
PRMT5 depletion also had little effect on SHEP cells without
high MYCN (see below). Increased cell death and PARP cleav-
age consistent with apoptosis was also apparent in NGP cells
transfected with PRMT5 siRNA (Figure 2B and C).
3.2. PRMT5 expression correlates with MYCN in
primary neuroblastomas
Both SK-N-BE(2)C and NGP cells are known to have MYCN
amplification and high MYCN protein expression, whereas
SH-SY5Y cells do not, suggesting a relation between PRMT5
and MYCN expression. Examination of PRMT5 expression in
NB cell-lines confirmed that MYCN over-expression was asso-
ciated with higher PRMT5 protein levels (P ¼ 0.004, Man-
neWhitney U test) (Figure 3AeB). At the RNA level, in silico
analysis shows that high PRMT5 transcripts also correlate
with MYCN amplification status (P ¼ 2.0e08) and with poorFigure 2 e PRMT5 knockdown induces apoptosis in the NGP cell-line, bu
NGP cells, together with knockdown verification by immunoblotting. No ph
of NGP cell death by cell counting, the asterisk signifying significance (P
immunoblotting following PRMT5 knockdown.overall prognosis (P ¼ 2.2e08) (Figure S2A). Notably, however,
elevated PRMT5 mRNA levels were also associated with poor
outcome in MYCN-unamplified tumours (P ¼ 1.7e06)
(Figure S2B), alluding to a possible MYCN-independent onco-
genic role for PRMT5 in NB. For example, PRMT5 has been
shown to regulate cell-cycle progression (Scoumanne et al.,
2009) andmodify other proteins involved in NB tumorigenesis,
such as E2F-1 and p53 (Jansson et al., 2008; Cho et al., 2012).
We further examined PRMT5 protein expression in primary
NB tumour sections by immunohistochemistry. As shown in
Figure 3C, diffuse cytoplasmic staining was observed with
the PRMT5 antibody in normal ganglion in both ganglion
and satellite cells. Similarly, in a ganglioneuroma, tumour
cells showed cytoplasmic PRMT5 with no nuclear staining.
This pattern was also observed in a differentiating neuroblas-
toma without MYCN amplification. In poorly differentiated
neuroblastomas lacking MYCN amplification, 57% (n ¼ 14)
showed predominant nuclear staining whereas 43% showed
equal or more staining in the cytoplasm. In striking contrast,
poorly differentiated MYCN-amplified tumours showed
intense nuclear PRMT5 staining together with weaker cyto-
plasmic staining. In total, 89% (n ¼ 9) poorly differentiated
MYCN-amplified neuroblastomas showed predominant nu-
clear staining, whereas only 22% of a group including ganglio-
neuromas, ganglioneuroblastomas and differentiating
neuroblastoma (n¼ 9) showed equivalent or increased nucleart not in the SH-SY5Y cell-line. (A) Cell death triggered by PRMT5 in
enotypic changes were observed in SH-SY5Y cells. (B) Quantification
< 0.05). (C) Confirmation of increased cleaved PARP (cPARP) by
Figure 3 e PRMT5 and MYCN protein expression correlations in neuroblastoma. (A) Immunoblotting of PRMT5 in NB cell-lines without
MYCN amplification (MYCN-un) and cells with amplification (MYCN-A). Vinculin is used as a loading control. (B) A box plot showing PRMT5
levels normalised to vinculin in cell-lines demonstrates a significant over-expression of PRMT5 in MYCN-A lines (P< 0.004, ManneWhitney U
test). (C) Immunohistochemical staining of NB sections for PRMT5 protein: the top row shows a normal ganglion (g) with cytoplasmic PRMT5
staining arrowed, and Schwannian stroma (ss), followed by a ganglioneuroma with differentiating neuroblasts (d) with cytoplasmic PRMT5
staining arrowed, and finally a differentiating NB, again with cytoplasmic PRMT5. The second row shows differentiating neuroblastomas without
MYCN amplification showing predominantly cytoplasmic PRMT5 expression. Neuroblasts (n) and Homer Wright rosettes (hw) are indicated. The
third row shows poorly differentiated neuroblastomas with MYCN amplification displaying intense nuclear PRMT5 staining. For PRMT5
immunohistochemistry controls, we used skeletal muscle which is negative for PRMT5 and normal prostate where PRMT5 expression has been
reported to be strong in the nucleus of the epithelial cells (Gu et al., 2012) (Figure S3).
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expression analyses strongly suggest a PRMT5-MYCN onco-
genic axis in NB.
The nuclear co-expression of PRMT5 and MYCN in poor
prognosis NBs alludes to a co-operative function for these pro-
teins in gene regulation, including the possible targeting of
PRMT5 to gene promoters by MYCN. We therefore tested
whether ST7 and RBL2 genes might also be targeted by
PRMT5/MYCN in NB. These genes are established PRMT5-
silenced TSGs in other cancers (Pal et al., 2004; Chung et al.,
2013), However, little or no change was observed in their tran-
script levelswith either PRMT5 orMYCNknockdowns.Wealso
assessed some genes encoding regulators of neuroblast differ-
entiation and cell death which are known to be repressed by
MYCN together with histone deacetylase 1, specifically NTRK
and NGFR (Iraci et al., 2011). Whilst both genes were reacti-
vated following MYCN knockdown, only NGFR mRNA was
markedly increased (over 3-fold) with PRMT5 knockdown in
NGP cells, with little effect being apparent in SK-N-BE(2)C cells
(Figure S4A). Thus PRMT5 and MYCN may co-operate in
silencing of NGFR in NGP cells. A comprehensive analysis of
PRMT5-and MYCN-regulated gene signatures and promoter
recruitment will be required to fully assess co-operative
gene regulation exerted by PRMT5 and MYCN.3.3. PRMT5 is a key regulator of the MYCN protein
To further investigate the strong association between PRMT5
and MYCN status, we next examined the effect of PRMT5
knockdown on MYCN in SK-N-BE(2)C, NGP and Kelly cell-
lines, all of which have MYCN amplification. As shown in
Figure 4A, PRMT5 depletion was accompanied by a dramatic
decrease of MYCN protein with two independent PRMT5 siR-
NAs, thereby negating the possibility of off-target effects.
Notably, the PRMT5-dependent MYCN decrease in NGP cells
suggests an alternative mechanism for PRMT5 compared to
the BET domain inhibitor JQ-1, which did not affect MYCN in
NGP cells (Puissant et al., 2013). MYCN transcript levels were
onlymoderately decreased accompanying PRMT5 knockdown
(Figure S4B), suggesting that PRMT5 mediates MYCN regula-
tion at post-transcriptional levels, although we cannot
currently exclude composite effects including indirect tran-
scriptional regulation, for example by PRMT5 depletion lead-
ing to reactivation of epigenetically silenced MYCN repressor
proteins or microRNAs.
We also evaluated PRMT5 knockdown in the SHEP-Tet21N
cell-line, which has inducible MYCN expression following
removal of tetracycline (Figure 4BeD). PRMT5 depletion led
to reduced MYCN and a statistically significant increase in
Figure 4 eMYCN depletion triggered by PRMT5 knockdown. (A) Immunoblot analysis showing MYCN depletion in SK-N-BE(2)C, NGP and
Kelly NB cell-lines following transfection with two independent PRMT5 siRNAs, negating the possibility of off-target effects. (B) PRMT5
knockdown in the SHEP-Tet21N cell-line harbouring inducible MYCN expression. MYCN is switched off in the presence of tetracycline (DTet)
and induced after its removal (LTet). Cell death is clearly visible in the MYCN-on cells after PRMT5 knockdown. (C) Cell counts showing
significantly increased cell death (asterisked, P< 0.005, Student’s t-test) after PRMT5 knockdown in cells induced to express MYCN. A
statistically insignificant change (not significant, ns) is observed in MYCN-off cells. (D) Immunoblots of SHEP-Tet21N cells demonstrating that
PRMT5 also affects MYCN expressed from the inducible transgene. Depletion is accompanied by an increase in cleaved PARP indicative of
apoptosis.
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cells without induced MYCN did not show a significant in-
crease in cell death. Immunoblotting also showed an increase
in cleaved PARP indicative of apoptosis accompanying PRMT5
knockdown in the induced cells.Figure 5 e PRMT5 regulates MYCN stability. (A) Cycloheximide (CHX)
(siPRMT5) knockdown in NGP cells (left) and SHEP-21N cells (right). (B
assays. MYCN levels are normalised relative to b-actin.In order to assess PRMT5 influence on post-translational
MYCN stability, we conducted cycloheximide chase assays
on PRMT5 siRNA transfected cells. As shown in Figure 5A-B,
MYCN is turned over with a half-life of approximately
90 min in NGP cells transfected with negative control siRNA,treated samples analysis following negative control (siVE) or PRMT5
) Plots of densitometric quantification of MYCN protein stability
Figure 6 e Cell-cycle changes accompanying PRMT5 knockdowns. Following PRMT5 knockdown, moderate increases in G1 were apparent in
NGP and Kelly cell-lines, and statistically significant G1-arrest was apparent in uninduced SHEP-Tet21N cells (asterisked, P< 0.0001,
Student’s t-test). In induced SHEP-Tet21N cells, no G1-arrest was evident; however a significant G2/M-phase decrease was apparent (asterisked,
P< 0.005). The latter analysis was done with duplicate samples.
Figure 7 e Physical interaction between endogenous PRMT5 and
MYCN. (A) Co-immunoprecipitation (IP) of MYCN with anti-
PRMT5 antibody (left) and the reciprocal co-immunoprecipitation
(right) in NGP cells. (B) Co-immunoprecipitations as above in SK-
N-BE(2)C cells.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 6 1 7e6 2 7624but the half-life is dramatically decreased to approximately
22 min in cells transfected with PRMT5 siRNA. Similarly, in
induced SHEP-Tet21N cells, MYCN protein exhibits a half-life
of approximately 46 min, which is reduced to approximately
18 min after PRMT5 knockdown.
In neuronal progenitor cells, MYCN is proteosomally regu-
lated during mitosis (Sjostrom et al., 2005), so we investigated
whether the PRMT5-depletion effect on MYCN might be indi-
rect and attributable to solely to G1 cell-cycle arrest. Whilst
a degree of G1 arrest was apparent in NGP and Kelly cells after
PRMT5 knockdown, it was below statistical significance
(Figure 6A and B). Furthermore, G1 arrest was not observed af-
ter PRMT5 knockdown in SHEP-Tet21N cells overexpressing
MYCN, in contrast to uninduced SHEP-Tet21N cells where G1
arrest was pronounced (Figure 6C). Interestingly however,
MYCN-induced SHEP-Tet21N cells exhibited a significant
decrease of cells in G2/M-phase after PRMT5 knockdown
(P < 0.005), concomitant with an increase of cells in S-phase.
A similar effect on S-phase has been demonstrated for c-
myc in medulloblastoma cells (Zhang et al., 2006). Together
these experiments strongly support PRMT5 being able to
directly influence MYCN protein stability and modulate its
biological activities.
3.4. Physical and functional interaction of PRMT5 and
MYCN
We next sought to establish whether endogenous PRMT5
physically associated with MYCN complexes in NGP and SK-
N-BE(2)C cells, as such an interaction may serve to stabilise
MYCN and provide initial evidence that MYCNmight be a sub-
strate for the argininemethyltransferase activity of PRMT5. As
shown in Figure 7A, MYCNwas easily detected in PRMT5 com-
plexes immunoprecipitated from NGP extracts and PRMT5
was also confirmed in the reciprocal MYCNimmunoprecipitation. This robust interaction was also
apparent in SK-N-BE(2)C cells (Figure 7B), and is consistent
with the notion that PRMT5 is capable of stabilizing MYCN
at the protein level.
Lastly, we assessedwhetherMYCNproteinmay bemethyl-
ated by PRMT5 using liquid chromatography e tandem mass
spectrometry (LC-MS/MS) analysis of immunoprecipitated
MYCN protein from SK-N-BE(2)C cells before and after
PRMT5 knockdown. This analysis gave us >53% coverage of
MYCN, and identified several potential sites of argininemono-
methylation and dimethylation on the MYCN protein
(Figure S5). By inspecting spectra of MYCN peptides bio-
informatically predicted to contain arginine methylation, we
pinpointed R160, R238 and R242 as high probability sites for
dimethylation. Discerning asymmetric and symmetric
Figure 8 e Detection of dimethylated arginine residues in MYCN. (A) LC-MS/MS MS/MS spectrum of the doubly dimethylated peptide,
EPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGR (m/z 1211.66, 3D) from MYCN immunoprecipitated after control siRNA knockdown. The majority of ions are due to doubly
charged C-terminal y ions, which show that the two C-terminal arginine residues are dimethylated (underlined arginines are dimethylated). (B) MS/MS spectrum of the singly dimethylated peptide
EPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGR (m/z 1202.30, 3D) from MYCN immunoprecipitated after PRMT5 knockdown. The doubly charged C-terminal fragment ions in
this spectrum are 14 m/z units (corresponding to a mass difference of 28 Da) lower than those shown in (A) as a result of the absence of a second dimethylated arginine residue, corresponding to R242 in
MYCN (see Figure S5).
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However, by manually comparing the spectra for the peptide
containing R238 and R242, from control siRNA and PRMT5
siRNA treated samples, we were able to identify fragment
ions with reduced mass in the PRMT5 knockdown sample,
consistent with the loss of dimethylarginine at R242
(Figure 8). The double-dimethylated peptide shown in
Figure 8A was not found in MYCN from PRMT5 knockdown,
consistent with R242 representing a primary target for
PRMT5 methyltransferase activity. However, it is important
to note that our analysis was not quantitative and would
therefore not allow us to identify subtler changes occurring
between samples. Nevertheless, these experiments demon-
strate for the first time that MYCN undergoes PTM by arginine
methylation, and mechanistically implicate PRMT5 as a crit-
ical regulator of MYCN protein levels.4. Conclusion
PRMT5 has pleiotropic regulatory roles in the cytoplasm and
nucleus in normal cells, and has been shown to be crucial
for normal development (Karkhanis et al., 2011), emphasising
the importance of defining PRMT5 substrates in normal and
cancer cells. Here we show for the first time that MYCN is a
novel PRMT5 target that is regulated by post-translational
arginine methylation. The interplay of MYCN methylation
and phosphorylation in regulating MYCN remains to be eluci-
dated. As MYCN is an oncogenic driver in a wide variety of
cancers, our findings highlight the importance of developing
PRMT5 small molecule inhibitors for cancer therapeutics tar-
geting MYCN; currently no specific inhibitors are available.
Additionally, our data on NGFR reactivation by PRMT5 knock-
down also suggest that PRMT5 is a co-operative co-repressor
for MYCN-mediated gene regulation. This is also supported
by the report that the gene encoding MEP50/WDR77, which
is a key component necessary for PRMT5 enzymatic activity,
is positively regulated by MYCN (Valentijn et al., 2012).
Furthermore, this raises the intriguing possibility that MYCN
may have an additional regulatory mode involving directing
global post-translational modifications by arginine methyl-
ation. These possibilities are currently being examined using
proteomic approaches in our laboratories.Conflict of interest
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